Addex Therapeutics Ltd (0QNV.L) Comparison with companies in other sectors?

Addex Therapeutics Ltd has a share price of 27.78M. You can analyze Addex Therapeutics Ltd (0QNV.L) competitors across different market sectors through stock heatmaps.

What are 0QNV.L's NET and operating margins?

Addex Therapeutics Ltd (0QNV.L) operating margin is around -10.45, and net profit margin is approximately 35.22 as of the latest reports.

In what way does 0QNV.L's earnings per share (EPS) trend reflect its financial momentum?

Addex Therapeutics Ltd (0QNV.L) EPS is -0.53 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Addex Therapeutics Ltd is -0.11, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Addex Therapeutics Ltd?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Addex Therapeutics Ltd like P/E which is 0.67, P/B which is 0.70, and PEG which is 0.03. Compare them with sector averages to evaluate if the stock is priced fairly.

Addex Therapeutics Ltd

0QNV.L•LSE

Healthcare

Biotechnology

£0.06

£-0.00(-1.35%)

Addex Therapeutics Ltd (0QNV.L) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.53

P/E Ratio

-0.11

ROE

0.83%

Net Margin

35.22%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$1.62M

Shares OutstandingTotal number of shares issued

$27.78M

Book Value/ShareNet worth per share

$0.08

Revenue/ShareAnnual revenue per share

$0.003

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.526

Net MarginNet income as percentage of revenue

3521.74%

Operating MarginOperating income as percentage of revenue

-1045.30%

ROEReturn on shareholders' equity

83.21%

ROAReturn on total assets

91.41%

ROCEReturn on capital employed

-30.53%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.04

Cash/ShareCash and equivalents per share

$0.03

FCF YieldFree cash flow as percentage of market cap

-34.76%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 0QNV.LFinancial Ratios Analysis details for 0QNV.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 0QNV.LSector Benchmarking details for 0QNV.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Addex Therapeutics Ltd Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Addex Therapeutics Ltd. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Addex Therapeutics Ltd's unique business strengths and challenges.

Key Financial Metrics for Addex Therapeutics Ltd

For Addex Therapeutics Ltd, essential financial indicators include EPS -0.53, PE -0.11, and ROE 0.83. These key ratios reveal insights into Addex Therapeutics Ltd's profitability, valuation, and operational health. Understanding these metrics enables you to compare Addex Therapeutics Ltd with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Addex Therapeutics Ltd

Metrics like Net Margin 3521.74% and ROA 91.41% shed light on how well Addex Therapeutics Ltd is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Addex Therapeutics Ltd can sustain its operations and continue growing in the future.

Valuation and Market Position of Addex Therapeutics Ltd

Using ratios such as P/B Ratio 0.70 and PEG Ratio 0.03, investors can assess whether Addex Therapeutics Ltd is appropriately valued based on its financials and growth potential. These figures, combined with Addex Therapeutics Ltd's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Addex Therapeutics Ltd

Financial health indicators, such as Debt/Equity Ratio 0.005 and Cash Flow $-0.04, provide a snapshot of Addex Therapeutics Ltd's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Addex Therapeutics Ltd, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Addex Therapeutics Ltd

Investing in Addex Therapeutics Ltd based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Addex Therapeutics Ltd focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;